Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 15, 1998

View Archived Issues

Capsazepine attenuates inflammation-induced hyperalgesic responses

Melanotan II effective as a treatment for psychogenic erectile dysfunction

rAd/p21: an effective gene therapy approach for treating lung cancer

OraPharma's periodontal disease Rx enters phase III testing

Adrenergic agents for BPH described by Abbott in patent literature

MRI contrast agents in development at Nycomed Imaging

Antigestagenic steroid esters patented by Schering AG

Amgen describes preparation and use of KGF proteins

New Asta development candidate represents new type of PDE4 inhibitor

F-12682: new 5-HT1B/1D receptor inverse agonist for depression

Interneuron receives U.S. patent protection for stroke Rx

SmithKline Beecham research leads to discovery of potent and selective 5-HT7 antagonists

Potent mGluR1/mGluR5 receptor antagonist presented by Lilly at EFMC symposium

Pierre Fabre describes pharmacological profile of F-11440 -- new high-efficacy 5-HT1A agonist

Novel glucagon receptor antagonist with potential in treating type I/type II diabetes

Aviron's FluMist PLA/ELA deemed nonfilable by FDA; resubmission planned

Wyeth-Lederle researchers discover potential treatment for RSV infection

Scios will copromote SmithKline Beecham's SSRI

Boston Biomedica's newest anti-HIV candidates receive patent protection in U.S.

FDA accepts Dusa's NDA for filing

Inflammatory/immunological disease collaboration initiated by BMS and Molecumetics

Viragen acquires stake in Inflammatics; adds LeukoVAX to pipeline

Cerebrus enters into collaborative agreement with Lilly for CEB-1555

First phase III MS results reported for Novantrone

U.S. patent issues for Cylexin

Maxim enters collaborative agreement with BioNative

Onyx discovers another therapeutic virus for cancer therapy

Hycamtin receives first approval for small cell lung cancer in Switzerland

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.